- Academic Editor
-
-
-
Background: An example of a sodium-glucose cotransporter-2 (SGLT-2)
inhibitor is Empagliflozin. It is a new medicine for treating type 2 diabetes
mellitus (T2DM), but there is increasing interest in how empagliflozin affects
the heart. This study aims to examine the impact of empagliflozin treatment on
ventricular repolarization parameters in T2DM patients. Methods: T2DM
patients were included in a prospective study. Measurements of ventricular
repolarization parameters, including QT interval, corrected QT interval (QTc), QT
dispersion (QTd), Tpeak-to-Tend interval (Tp-e), and Tpeak-to-Tend interval
corrected for QTc (Tp-e/QTc), were obtained before initiating empagliflozin
treatment and six months following treatment initiation. Statistical analysis was
performed to assess changes in these parameters. Results: In this study,
95 patients were diagnosed with T2DM out of 177 patients. Among T2DM patients, 40
were male (42%) compared to 48% males in controls (p = 0.152). The
average age of the T2DM patients was 60.2